Citius Oncology, Inc.
CTOR
$0.94
$0.011.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 66.46% | -380.83% | -10.76% | 6.95% | 30.58% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -222.90% | 200.02% | -- | -- | -- |
| Total Other Non-Cash Items | 126.60% | -21.91% | 64.70% | 7.24% | 1.56% |
| Change in Net Operating Assets | -95.16% | 368.53% | -116.32% | -202.59% | -44.63% |
| Cash from Operations | 29.26% | 47.90% | -33.92% | -- | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -233.33% | 86.36% | 23.48% | -- | -- |
| Cash from Investing | -233.33% | 86.36% | 23.48% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -0.27% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -327.23% | -- | -- | -- | -- |
| Cash from Financing | 8,163.02% | -101.53% | -0.27% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 398.77% | -238.34% | -14.12% | -- | -- |